Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:2015:860861.
doi: 10.1155/2015/860861. Epub 2015 May 19.

Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management

Kelly J Lafaro  1 , David Cosgrove  2 , Jean-Francois H Geschwind  3 , Ihab Kamel  3 , Joseph M Herman  4 , Timothy M Pawlik  1
Affiliations
Review

Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management

Kelly J Lafaro et al. Gastroenterol Res Pract. 2015.

Abstract

Cholangiocarcinoma is a highly fatal primary cancer of the bile ducts which arises from malignant transformation of bile duct epithelium. While being an uncommon malignancy with an annual incidence in the United States of 5000 new cases, the incidence has been increasing over the past 30 years and comprises 3% of all gastrointestinal cancers. Cholangiocarcinoma can be classified into intrahepatic (ICC) and extrahepatic (including hilar and distal bile duct) according to its anatomic location within the biliary tree with respect to the liver. This paper reviews the management of ICC, focusing on the epidemiology, risk factors, diagnosis, and surgical and nonsurgical management.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment algorithm for intrahepatic cholangiocarcinoma.
Figure 2
Figure 2
MRI and pathologic correlation of intrahepatic cholangiocarcinoma. (a) Yellow-grey intrahepatic mass on pathologic specimen. (b) Portal venous phase MRI of intrahepatic cholangiocarcinoma designated by box with hypointense lesion. (c) Delayed contrast-enhanced MRI of the same lesion showing accumulation of contrast within the lesion. Reprinted from Cancer Imaging [42].
Figure 3
Figure 3
Signaling pathways involved in intrahepatic cholangiocarcinoma and the corresponding molecular therapies. Reprinted from McMilan Publishers Ltd.: Oncogene [97].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fan B., Malato Y., Calvisi D. F., et al. Cholangiocarcinomas can originate from hepatocytes in mice. The Journal of Clinical Investigation. 2012;122(8):2911–2915. doi: 10.1172/jci63212. - DOI - PMC - PubMed
    1. Sekiya S., Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. The Journal of Clinical Investigation. 2012;122(11):3914–3918. doi: 10.1172/jci63065. - DOI - PMC - PubMed
    1. Bridgewater J., Galle P. R., Khan S. A., et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. Journal of Hepatology. 2014;60(6):1268–1289. doi: 10.1016/j.jhep.2014.01.021. - DOI - PubMed
    1. Bragazzi M. C., Cardinale V., Carpino G., et al. Cholangiocarcinoma: epidemiology and risk factors. Translational Gastrointestinal Cancer. 2012;1:21–32.
    1. Poultsides G. A., Zhu A. X., Choti M. A., Pawlik T. M. Intrahepatic cholangiocarcinoma. Surgical Clinics of North America. 2010;90(4):817–837. doi: 10.1016/j.suc.2010.04.011. - DOI - PubMed

LinkOut - more resources